Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases

Irene Marafini, Giovanni Monteleone Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence: Giovanni MonteleoneDipartimento di Medicina dei Sistemi, Università di Roma “Tor Vergata”, via Montpellier, 1, Rome 0013...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marafini I, Monteleone G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	crohn’s disease ulcerative colitis icam-1 smad7 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8d23af80a2684fe7936e31495ba02cbc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d23af80a2684fe7936e31495ba02cbc
record_format	dspace
spelling	oai:doaj.org-article:8d23af80a2684fe7936e31495ba02cbc2021-12-02T11:08:04ZTherapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases1177-5491https://doaj.org/article/8d23af80a2684fe7936e31495ba02cbc2020-06-01T00:00:00Zhttps://www.dovepress.com/therapeutic-oligonucleotides-for-patients-with-inflammatory-bowel-dise-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Irene Marafini, Giovanni Monteleone Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence: Giovanni MonteleoneDipartimento di Medicina dei Sistemi, Università di Roma “Tor Vergata”, via Montpellier, 1, Rome 00133, ItalyTel +390620903702Fax +390672596391Email Gi.Monteleone@Med.uniroma2.itIntroduction: The better understanding of the molecular mechanisms, which drive the pathological process in the gut of patients with Crohn’s disease (CD) and patients with ulcerative colitis (UC), the major forms of inflammatory bowel diseases (IBD) in humans, has facilitated the development of novel therapeutic compounds. Among these, antisense oligonucleotides (ASOs) have been used to inhibit the expression of molecules, which sustain the IBD-associated mucosal inflammation.Areas Covered: In this short review, we summarize experimental and clinical data on the use of ASOs in IBD.Expert Opinion: Preclinical work indicates that the modulation of specific inflammatory pathways through the use of ASOs is highly effective and associates with low risk of adverse events. Initial clinical studies have confirmed the benefit of some ASOs even though no compound has yet reached the market. Further experimentation is warranted to establish the optimal route of administration for each ASO, ascertain whether and how long ASOs maintain their activity following administration, and identify which patient can benefit from specific ASO treatment.Keywords: Crohn’s disease, ulcerative colitis, ICAM-1, Smad7Marafini IMonteleone GDove Medical Pressarticlecrohn’s diseaseulcerative colitisicam-1smad7Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 47-51 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	crohn’s disease ulcerative colitis icam-1 smad7 Medicine (General) R5-920
spellingShingle	crohn’s disease ulcerative colitis icam-1 smad7 Medicine (General) R5-920 Marafini I Monteleone G Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
description	Irene Marafini, Giovanni Monteleone Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence: Giovanni MonteleoneDipartimento di Medicina dei Sistemi, Università di Roma “Tor Vergata”, via Montpellier, 1, Rome 00133, ItalyTel +390620903702Fax +390672596391Email Gi.Monteleone@Med.uniroma2.itIntroduction: The better understanding of the molecular mechanisms, which drive the pathological process in the gut of patients with Crohn’s disease (CD) and patients with ulcerative colitis (UC), the major forms of inflammatory bowel diseases (IBD) in humans, has facilitated the development of novel therapeutic compounds. Among these, antisense oligonucleotides (ASOs) have been used to inhibit the expression of molecules, which sustain the IBD-associated mucosal inflammation.Areas Covered: In this short review, we summarize experimental and clinical data on the use of ASOs in IBD.Expert Opinion: Preclinical work indicates that the modulation of specific inflammatory pathways through the use of ASOs is highly effective and associates with low risk of adverse events. Initial clinical studies have confirmed the benefit of some ASOs even though no compound has yet reached the market. Further experimentation is warranted to establish the optimal route of administration for each ASO, ascertain whether and how long ASOs maintain their activity following administration, and identify which patient can benefit from specific ASO treatment.Keywords: Crohn’s disease, ulcerative colitis, ICAM-1, Smad7
format	article
author	Marafini I Monteleone G
author_facet	Marafini I Monteleone G
author_sort	Marafini I
title	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
title_short	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
title_full	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
title_fullStr	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
title_full_unstemmed	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
title_sort	therapeutic oligonucleotides for patients with inflammatory bowel diseases
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8d23af80a2684fe7936e31495ba02cbc
work_keys_str_mv	AT marafinii therapeuticoligonucleotidesforpatientswithinflammatoryboweldiseases AT monteleoneg therapeuticoligonucleotidesforpatientswithinflammatoryboweldiseases
_version_	1718396232236269568

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases

Ejemplares similares